Citations (108)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Joshua Barnett & Sofia Pappa. (2023) Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety. Patient Preference and Adherence 17, pages 1603-1610.
Read now
Read now
Lee Seng Esmond Seow, Jue Hua Lau, Edimansyah Abdin, Swapna K. Verma, Kelvin Bryan Tan & Mythily Subramaniam. (2023) Mapping the schizophrenia quality of life scale to EQ-5D, HUI3 and SF-6D utility scores in patients with schizophrenia. Expert Review of Pharmacoeconomics & Outcomes Research 23:7, pages 813-821.
Read now
Read now
Ajay Nair, Amanie Salem, Anna-Lee Asamoah, Ravipreet Gosal & George T Grossberg. (2020) An update on the efficacy and safety of iloperidone as a schizophrenia therapy. Expert Opinion on Pharmacotherapy 21:15, pages 1793-1798.
Read now
Read now
P Piyabhan, P Tingpej & N Duansak. (2019) Effect of pre- and post-treatment with Bacopa monnieri (Brahmi) on phencyclidine-induced disruptions in object recognition memory and cerebral calbindin, parvalbumin, and calretinin immunoreactivity in rats. Neuropsychiatric Disease and Treatment 15, pages 1103-1117.
Read now
Read now
Dominic Pilon, Matthew Alcusky, Yongling Xiao, Philippe Thompson-Leduc, Marie-Hélène Lafeuille, Patrick Lefebvre & Carmela Benson. (2018) Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. Journal of Medical Economics 21:2, pages 135-143.
Read now
Read now
Michaela Holubova, Jan Prasko, Klara Latalova, Marie Ociskova, Aleš Grambal, Dana Kamaradova, Kristyna Vrbova & Radovan Hruby. (2016) Are self-stigma, quality of life, and clinical data interrelated in schizophrenia spectrum patients? A cross-sectional outpatient study. Patient Preference and Adherence 10, pages 265-274.
Read now
Read now
Wesley Williams, Christopher McKinney, Larry Martinez & Carmela Benson. (2016) Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery. Journal of Medical Economics 19:5, pages 469-476.
Read now
Read now
Shaloo Gupta, Gina Isherwood, Kevin Jones & Kristel Van Impe. (2015) Productivity loss and resource utilization, and associated indirect and direct costs in individuals providing care for adults with schizophrenia in the EU5. ClinicoEconomics and Outcomes Research 7, pages 593-602.
Read now
Read now
Articles from other publishers (100)
Carla Morales-Pillado, Belén Fernández-Castilla, Teresa Sánchez-Gutiérrez, Eduardo González-Fraile, Sara Barbeito & Ana Calvo. (2022) Efficacy of technology-based interventions in psychosis: a systematic review and network meta-analysis. Psychological Medicine 53:13, pages 6304-6315.
Crossref
Crossref
Seda Attepe Özden, Melike Tekindal & Mustafa Agah Tekindal. (2023) Quality of Life of people with Schizophrenia: A meta-analysis. International Journal of Social Psychiatry 69:6, pages 1444-1452.
Crossref
Crossref
Tomonari Hosokawa, Chikara Miyaji, Yusaku Yoshimura, Kenji Washida, Yuji Yada, Shinji Sakamoto, Yuko Okahisa, Soshi Takao, Akira Nomura, Yoshiki Kishi, Toshiki Harada, Manabu Takaki, Toshihiko Takeda & Norihito Yamada. (2023) Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting. Psychopharmacology 240:9, pages 1911-1920.
Crossref
Crossref
Selma Ercan Doğu & Sibel Örsel. (2022) The relationship between psychopathology, occupational balance, and quality of life among people with schizophrenia. Australian Occupational Therapy Journal 70:3, pages 314-326.
Crossref
Crossref
Sagnik Bhattacharyya, Tabea Schoeler, Marta Di Forti, Robin Murray, Alexis E Cullen & Marco Colizzi. (2023) Stressful life events and relapse of psychosis: analysis of causal association in a 2-year prospective observational cohort of individuals with first-episode psychosis in the UK. The Lancet Psychiatry 10:6, pages 414-425.
Crossref
Crossref
Daniella Mahfoud, Jad El Ahdab, Sami Helwe, Michael Topalian, Christina Tarabay, Karim Rifi, Georges Haddad, Sahar Obeid & Souheil Hallit. (2023) The Indirect Effect of Depression between Nightmares and Well-Being in Lebanese Patients with Schizophrenia. Perspectives in Psychiatric Care 2023, pages 1-9.
Crossref
Crossref
Kenji Baba, Wenjia Guo, Yirong Chen, Tadashi Nosaka & Tadafumi Kato. (2022) Burden of schizophrenia among Japanese patients: a cross-sectional National Health and Wellness Survey. BMC Psychiatry 22:1.
Crossref
Crossref
Ingrid T. Johansen, Nils Eiel Steen, Linn Rødevand, Maren C.F. Werner, Synve H. Lunding, Gabriela Hjell, Monica B.E.G. Ormerod, Ingrid Agartz, Ingrid Melle, Trine V. Lagerberg, Mari Nerhus & Ole A. Andreassen. (2022) Sex-specific associations between metabolic hormones, severe mental disorders and antipsychotic treatment. Psychoneuroendocrinology 146, pages 105927.
Crossref
Crossref
Ali Fattah Al-Musawi, Hussein Kadhem Al-Hakeim, Zahraa Abdulrazaq Al-Khfaji, Inas H. Al-Haboby, Abbas F. Almulla, Drozdstoj St. Stoyanov & Michael Maes. (2022) In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatome. International Journal of Environmental Research and Public Health 19:22, pages 15281.
Crossref
Crossref
Deborah J. Luessen & P. Jeffrey Conn. (2022) Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease. Pharmacological Reviews 74:3, pages 630-661.
Crossref
Crossref
Ingrid Torp Johansen, Nils Eiel Steen, Marit Haram, Linn Rødevand, Maren C.F. Werner, Synve Hoffart Lunding, Gabriela Hjell, Ingrid Agartz, Ingrid Melle, Trine V. Lagerberg, Mari Nerhus & Ole A. Andreassen. (2022) Sex differences in antipsychotic-related triglyceride levels are associated with metabolic hormone differences in patients with severe mental disorders. Schizophrenia Research 243, pages 55-63.
Crossref
Crossref
Marinela Hurmuz, Mirela Frandes, Anca-Livia Panfil, Ileana-Pepita Stoica, Cristina Bredicean, Catalina Giurgi-Oncu, Ion Papava & Aurel Nirestean. (2022) Quality of Life in Patients with Chronic Psychotic Disorders: A Practical Model for Interventions in Romanian Mental Health Centers. Medicina 58:5, pages 615.
Crossref
Crossref
Pernille Kølbæk, Mette Viller Thorgaard, Amalie Schnegelsberg Grooss, Thusitha Selvanathan, Sofie Fly Larsen, Maria Speed, David Dines & Søren Dinesen Østergaard. (2022) Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ). Journal of Psychopharmacology 36:4, pages 507-515.
Crossref
Crossref
Mélissa Beaudoin, Alexandre Hudon, Charles-Edouard Giguère, Stéphane Potvin & Alexandre Dumais. (2022) Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophrenia 8:1.
Crossref
Crossref
LeeAnn Akouri-Shan, Joseph S. DeLuca, Steven C. Pitts, Samantha Y. Jay, Samantha L. Redman, Emily Petti, Miranda A. Bridgwater, Pamela J. Rakhshan Rouhakhtar, Mallory J. Klaunig, Doha Chibani, Elizabeth A. Martin, Gloria M. Reeves & Jason Schiffman. (2022) Internalized stigma mediates the relation between psychosis-risk symptoms and subjective quality of life in a help-seeking sample. Schizophrenia Research 241, pages 298-305.
Crossref
Crossref
Gurpreet Rekhi, Jenny Tay & Jimmy Lee. (2022) Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia. Journal of Psychopharmacology 36:2, pages 183-190.
Crossref
Crossref
Nadja MarićP.P., Ivan Ristić, Stefan Jerotić, Sanja Andrić-Petrović, Bojana Savić, Mirjana Zebić, Kristina Savić, Teodora Tomić & Nikolina Jovanović. (2022) Recovering quality of life in outpatients with psychosis spectrum disorders and its association with the symptom domains. Medicinska istrazivanja 55:1, pages 43-49.
Crossref
Crossref
Peizhi Wang, Edimansyah Abdin, P.V. Asharani, Vanessa Seet, Fiona Devi, Kumarasan Roystonn, Ying Ying Lee, Laxman Cetty, Wen Lin Teh, Swapna Verma, Yee Ming Mok & Mythily Subramaniam. (2021) Nicotine Dependence in Patients with Major Depressive Disorder and Psychotic Disorders and Its Relationship with Quality of Life. International Journal of Environmental Research and Public Health 18:24, pages 13035.
Crossref
Crossref
Joseph P. McEvoy, Peter J. Weiden, Paul H. Lysaker, Xiaowu Sun & Amy K. O’Sullivan. (2021) Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. BMC Psychiatry 21:1.
Crossref
Crossref
Laura Ortega, Itziar Montalvo, Rosa Monseny, Maria Dolors Burjales‐Martí, Lourdes Martorell, Vanessa Sanchez‐Gistau, Elisabet Vilella & Javier Labad. (2020) Perceived stress, social functioning and quality of life in first‐episode psychosis: A 1‐year follow‐up study. Early Intervention in Psychiatry 15:6, pages 1542-1550.
Crossref
Crossref
James Maksymetz, Nellie E. Byun, Deborah J. Luessen, Brianna Li, Robert L. Barry, John C. Gore, Colleen M. Niswender, Craig W. Lindsley, Max E. Joffe & P. Jeffrey Conn. (2021) mGlu1 potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits. Cell Reports 37:5, pages 109950.
Crossref
Crossref
Igor D. Bandeira, Judah L. Barouh, Ingrid D. Bandeira & Lucas Quarantini. (2020) Analysis of the superior temporal gyrus as a possible biomarker in schizophrenia using voxel-based morphometry of the brain magnetic resonance imaging: a comprehensive review. CNS Spectrums 26:4, pages 319-325.
Crossref
Crossref
István Laszlovszky, Ágota Barabássy & György Németh. (2021) Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Advances in Therapy 38:7, pages 3652-3673.
Crossref
Crossref
Julaeha Julaeha, Umi Athiyah, Margarita Maria Maramis, Agus Sugianto & Andi Hermansyah. (2021) Translation and cross-cultural adaption of an instrument measuring patient’s well-being under treatment for schizophrenia. Journal of Basic and Clinical Physiology and Pharmacology 32:4, pages 341-347.
Crossref
Crossref
Blanca Fernández-Abascal, Paula Suárez-Pinilla, Carlos Cobo-Corrales, Benedicto Crespo-Facorro & Marta Suárez-Pinilla. (2021) In- and outpatient lifestyle interventions on diet and exercise and their effect on physical and psychological health: a systematic review and meta-analysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode of psychosis. Neuroscience & Biobehavioral Reviews 125, pages 535-568.
Crossref
Crossref
Laura Dellazizzo, Stéphane Potvin, Kingsada Phraxayavong, Sabrina Giguère, Lyna-Nour Hamidi & Alexandre Dumais. (2021) L’amélioration de la qualité de vie chez les patients atteints d’une schizophrénie réfractaire ayant suivi la Thérapie assistée par la Réalité Virtuelle : une analyse de contenu. Santé mentale au Québec 46:1, pages 157-174.
Crossref
Crossref
Sandeep Grover, Chandrima Naskar & Subho Chakrabarti. (2021) Impact of clozapine on disability and course of illness in patients with schizophrenia: A study from North India. Indian Journal of Psychiatry 63:6, pages 588.
Crossref
Crossref
Áine Maguire, Christina Mooney, Grainne Flynn, Yolande Ferguson, Veronica O'Keane, Doreen O'Rourke, Tom McMonagle, Robert Heaton, Suzannah Phillips, Iain Hargreaves, Michael Gill & April Hargreaves. (2021) No Effect of Coenzyme Q10 on Cognitive Function, Psychological Symptoms, and Health-related Outcomes in Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychopharmacology 41:1, pages 53-57.
Crossref
Crossref
Wei Jie Ong, Xiao Wei Tan, Shazana Shahwan, Pratika Satghare, Laxman Cetty, Boon Tat Ng, Charmaine Tang, Swapna Verma, Siow Ann Chong & Mythily Subramaniam. (2020) Association between sleep quality and domains of quality of life amongst patients with first episode psychosis. Health and Quality of Life Outcomes 18:1.
Crossref
Crossref
Defaru Desalegn, Shimelis Girma & Tilahun Abdeta. (2020) Quality of life and its association with current substance use, medication non-adherence and clinical factors of people with schizophrenia in Southwest Ethiopia: a hospital-based cross-sectional study. Health and Quality of Life Outcomes 18:1.
Crossref
Crossref
Alexis Revet, François Montastruc, Anne Roussin, Jean-Philippe Raynaud, Maryse Lapeyre-Mestre & Thi Thu Ha Nguyen. (2020) Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry 20:1.
Crossref
Crossref
Tolesa Fanta, Desalegn Bekele & Getinet Ayano. (2020) The prevalence and associated factors of depression among patients with schizophrenia in Addis Ababa, Ethiopia, cross-sectional study. BMC Psychiatry 20:1.
Crossref
Crossref
Natasha Martland, Rebecca Martland, Alexis E. Cullen & Sagnik Bhattacharyya. (2020) Are adult stressful life events associated with psychotic relapse? A systematic review of 23 studies. Psychological Medicine 50:14, pages 2302-2316.
Crossref
Crossref
Minkyung Jo, Hyun-Jin Kim, Soo Jung Rim, Min Geu Lee, Chul Eung Kim & Subin Park. (2020) The cost-of-illness trend of schizophrenia in South Korea from 2006 to 2016. PLOS ONE 15:7, pages e0235736.
Crossref
Crossref
Martina Rojnic Kuzman, Porin Makaric, Dina Bosnjak Kuharic, Ivana Kekin, Zoran Madzarac, Ana Koricancic Makar, Zarko Bajic, Drazenka Ostojic, Ante Silic & Maja Zivkovic. (2020) General Functioning in Patients With First-Episode Psychosis After the First 18 Months of Treatment. Journal of Clinical Psychopharmacology 40:4, pages 366-372.
Crossref
Crossref
Isaac Jarratt-Barnham, Youssuf Saleh, Masud Husain, Brian Kirkpatrick & Emilio Fernandez-Egea. (2020) The influence of negative and affective symptoms on anhedonia self-report in schizophrenia. Comprehensive Psychiatry 98, pages 152165.
Crossref
Crossref
Defaru Desalegn, Shimelis Girma & Tilahun Abdeta. (2020) Quality of life and its association with psychiatric symptoms and socio-demographic characteristics among people with schizophrenia: A hospital-based cross-sectional study. PLOS ONE 15:2, pages e0229514.
Crossref
Crossref
Branko Ristić & Borjanka Batinić. (2020) Perception of emotions as a predictor of social functioning and the quality of life in patients with schizophrenia. Psiholoska istrazivanja 23:2, pages 161-185.
Crossref
Crossref
Xiao Wei Tan, Esmond Seow, Edimansyah Abdin, Swapna Verma, Kang Sim, Siow Ann Chong & Mythily Subramaniam. (2019) Subjective quality of life among patients with schizophrenia spectrum disorder and patients with major depressive disorder. BMC Psychiatry 19:1.
Crossref
Crossref
Kristiina Puolakka & Anneli Pitkänen. (2019) Effectiveness of psychosocial interventions on quality of life of patients with schizophrenia and related disorders: A systematic review. Archives of Psychiatric Nursing 33:5, pages 73-82.
Crossref
Crossref
Julia Sevilla‐Llewellyn‐Jones, Pablo Cano‐Domínguez, Antonia de‐Luis‐Matilla, Alberto Espina‐Eizaguirre, Berta Moreno‐Kustner & Susana Ochoa. (2017) Subjective quality of life in recent onset of psychosis patients and its association with sociodemographic variables, psychotic symptoms and clinical personality traits. Early Intervention in Psychiatry 13:3, pages 525-531.
Crossref
Crossref
Sunee Sirivichayakul, Buranee Kanchanatawan, Supaksorn Thika, André F. Carvalho & Michael Maes. (2019) A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions. CNS & Neurological Disorders - Drug Targets 18:2, pages 124-140.
Crossref
Crossref
Xiao Wei Tan, Shazana Shahwan, Pratika Satghare, Boon Yiang Chua, Swapna Verma, Charmaine Tang, Siow Ann Chong & Mythily Subramaniam. (2019) Trends in Subjective Quality of Life Among Patients With First Episode Psychosis—A 1 Year Longitudinal Study. Frontiers in Psychiatry 10.
Crossref
Crossref
Youssef Latifeh, Mays Mohsen, Sara Mohamad & Tarek Nassif. (2019) Olanzapine dose for people with schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Buranee Kanchanatawan, Sira Sriswasdi & Michael Maes. (2018) Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia. Metabolic Brain Disease 34:1, pages 267-282.
Crossref
Crossref
Laura B. Teal, Robert W. Gould, Andrew S. Felts & Carrie K. Jones. 2019. Neuropsychotherapeutics. Neuropsychotherapeutics
153
196
.
Madeline W. Z. Lim & Jimmy Lee. (2018) Determinants of Health-Related Quality of Life in Schizophrenia: Beyond the Medical Model. Frontiers in Psychiatry 9.
Crossref
Crossref
G. Gozlan, L. Lecardeur, A.-S. Monfort, M. Doz, I. Ortiz, P. Larroumets & A. Lafuma. (2018) Analyse coût-efficacité de l’aripiprazole injectable à libération prolongée (AILP) comparé au palmitate de palipéridone (PP) dans le traitement de la schizophrénie en France. L'Encéphale 44:6, pages 496-503.
Crossref
Crossref
Michael Y. Guo, Mahyar EtminanRic M. Procyshyn, David D. KimAli Samii, Abbas Kezouh & Bruce C. Carleton. (2018) Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms. Journal of Clinical Psychopharmacology 38:4, pages 349-356.
Crossref
Crossref
Hossein Ebrahimi, Naeimeh Seyedfatemi, Hossein Namdar Areshtanab, Fatemeh Ranjbar, Graham Thornicroft, Bill Whitehead & Farnaz Rahmani. (2018) Barriers to Family Caregivers’ Coping With Patients With Severe Mental Illness in Iran. Qualitative Health Research 28:6, pages 987-1001.
Crossref
Crossref
Alejandra Caqueo-Urízar, Marine Alessandrini & Laurent Boyer. (2018) Calidad de vida en pacientes con esquizofrenia de origen Aymara en la zona Centro-Sur de los Andes. Universitas Psychologica 16:5, pages 1-13.
Crossref
Crossref
Hyun Sook Park & Jae Woon Lee. (2018) Mediating Effect of Psychological Flexibility on Quality of Life in Inpatients with Schizophrenia. Journal of Korean Academy of Psychiatric and Mental Health Nursing 27:3, pages 284.
Crossref
Crossref
Robert W. Gould, Michael D. Grannan, Barak W. Gunter, Jacob Ball, Michael Bubser, Thomas M. Bridges, Jurgen Wess, Michael W. Wood, Nicholas J. Brandon, Mark E. Duggan, Colleen M. Niswender, Craig W. Lindsley, P. Jeffrey Conn & Carrie K. Jones. (2018) Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. Neuropharmacology 128, pages 492-502.
Crossref
Crossref
Anne Emilie Stürup, Heidi Dorthe Jensen, Signe Dolmer, Merete Birk, Nikolai Albert, Mai Nielsen, Carsten Hjorthøj, Lene Eplov, Bjørn H. Ebdrup, Ole Mors & Merete Nordentoft. (2017) TAILOR – tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. Trials 18:1.
Crossref
Crossref
James Maksymetz, Sean P. Moran & P. Jeffrey Conn. (2017) Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. Molecular Brain 10:1.
Crossref
Crossref
Joanne Lloyd, Helen Lloyd, Ray Fitzpatrick & Michele Peters. (2017) Treatment outcomes in schizophrenia: qualitative study of the views of family carers. BMC Psychiatry 17:1.
Crossref
Crossref
Neelam Laxhman, Lauren Greenberg & Stefan Priebe. (2017) Satisfaction with sex life among patients with schizophrenia. Schizophrenia Research 190, pages 63-67.
Crossref
Crossref
Stephen R. Marder, Mika Juhani Hakala, Mette Krog Josiassen, Peter Zhang, John Ouyang, Emmanuelle Weiller, Catherine Weiss & Mary Hobart. (2016) Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatrica 29:5, pages 278-290.
Crossref
Crossref
Caitlin Ridgewell, Jennifer Urbano Blackford, Maureen McHugo & Stephan Heckers. (2017) Personality traits predicting quality of life and overall functioning in schizophrenia. Schizophrenia Research 182, pages 19-23.
Crossref
Crossref
Laura R. Magni, Clarissa Ferrari, Giuseppe Rossi, Elena Staffieri, Aldo Uberti, Dario Lamonaca, Ileana Boggian, Silvia Merlin, Giuseppe Primerano, Alessandra Mombrini, Roberto Poli, Francesco M. Saviotti, Maria T. Caldera, Luciana Zanotti & Roberta Rossi. (2017) Superwellness Program: a cognitive-behavioral therapy-based group intervention to reduce weight gain in patients treated with antipsychotic drugs. Revista Brasileira de Psiquiatria 39:3, pages 244-251.
Crossref
Crossref
Wen-Yu Hsu, Chih-Hsin Muo, Szu-Pin Ma & Chia-Hung Kao. (2017) Association between schizophrenia and urinary incontinence: A population-based study. Psychiatry Research 248, pages 35-39.
Crossref
Crossref
David C. Cicero. 2017. Self-Concept Clarity. Self-Concept Clarity
219
242
.
Anna Klimowicz, Adriana Janicic & Waguih William IsHak. 2017. The Textbook of Clinical Sexual Medicine. The Textbook of Clinical Sexual Medicine
507
524
.
Susan M. Corley, Shan-Yuan Tsai, Marc R. Wilkins & Cynthia Shannon Weickert. (2016) Transcriptomic Analysis Shows Decreased Cortical Expression of NR4A1, NR4A2 and RXRB in Schizophrenia and Provides Evidence for Nuclear Receptor Dysregulation. PLOS ONE 11:12, pages e0166944.
Crossref
Crossref
Lin Xiao, Yulin Gao, Lili Zhang, Peiyun Chen & Xiaojia Sun. (2016) The relationship between cognitive function and quality of life in euthymic Chinese patients with bipolar disorder. Psychiatry Research 246, pages 427-431.
Crossref
Crossref
Yasuko Fuse-Nagase, Jun Miura, Ikuro Namura, Takeshi Sato, Katsuhiro Yasumi, Toshiyuki Marutani & Yoshiro Sugita. (2016) Decline in the severity or the incidence of schizophrenia in Japan: A survey of university students. Asian Journal of Psychiatry 24, pages 120-123.
Crossref
Crossref
F. Wartelsteiner, Y. Mizuno, B. Frajo‐Apor, G. Kemmler, S. Pardeller, C. Sondermann, A. Welte, W. W. Fleischhacker, H. Uchida & A. Hofer. (2016) Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and self‐esteem. Acta Psychiatrica Scandinavica 134:4, pages 360-367.
Crossref
Crossref
A. Shioda, E. Tadaka & A. Okochi. (2016) Loneliness and related factors among people with schizophrenia in Japan: a cross‐sectional study. Journal of Psychiatric and Mental Health Nursing 23:6-7, pages 399-408.
Crossref
Crossref
Robert W. Gould, Michael T. Nedelcovych, Xuewen Gong, Erica Tsai, Michael Bubser, Thomas M. Bridges, Michael R. Wood, Mark E. Duggan, Nicholas J. Brandon, John Dunlop, Michael W. Wood, Magnus Ivarsson, Meredith J. Noetzel, J. Scott Daniels, Colleen M. Niswender, Craig W. Lindsley, P. Jeffrey Conn & Carrie K. Jones. (2016) State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects. Neuropharmacology 102, pages 244-253.
Crossref
Crossref
Saibal Das, Preeti Barnwal, Blessed Winston A, Somnath Mondal & Indranil Saha. (2015) Brexpiprazole: so far so good. Therapeutic Advances in Psychopharmacology 6:1, pages 39-54.
Crossref
Crossref
Freya Nitka, Julia Richter, Peter Parzer, Franz Resch & Romy Henze. (2016) Health-related quality of life among adolescents: A comparison between subjects at ultra-high risk for psychosis and healthy controls. Psychiatry Research 235, pages 110-115.
Crossref
Crossref
Jo C. Neill, Ben Grayson, Béla Kiss, István Gyertyán, Paul Ferguson & Nika Adham. (2016) Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. European Neuropsychopharmacology 26:1, pages 3-14.
Crossref
Crossref
María Teresa Bobes-Bascarán, María Paz García-Portilla, Pilar A. Sáiz Martínez, Leticia García-Alvarez, Isabel Menéndez-Miranda, Susana Al-Halabí, María Teresa Bascarán & Julio Bobes. 2016. Beyond Assessment of Quality of Life in Schizophrenia. Beyond Assessment of Quality of Life in Schizophrenia
65
77
.
Santosh K. Chaturvedi, M. Krishna Prasad & Abhishek Pathak. 2016. Beyond Assessment of Quality of Life in Schizophrenia. Beyond Assessment of Quality of Life in Schizophrenia
197
215
.
Huali Lin, Ying Lei, Bo Zhang, Zunxiao Dai & Xiaoyun Lu. (2015)
Common variants of
HTR1A
and
SLC6A4
confer the increasing risk of Schizophrenia susceptibility: A population‐based association and epistasis analysis
. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 168:8, pages 749-755.
Crossref
Crossref
R. W. Gould, D. Dencker, M. Grannan, M. Bubser, X. Zhan, J. Wess, Z. Xiang, C. Locuson, C. W. Lindsley, P. J. Conn & C. K. Jones. (2015)
Role for the M
1
Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice
. ACS Chemical Neuroscience 6:10, pages 1683-1695.
Crossref
Crossref
Farooq Naeem, Shuo Xiang, Tariq A Munshi, David Kingdon & Saeed Farooq. (2015) Self-help and guided self-help interventions for schizophrenia and related disorders. Cochrane Database of Systematic Reviews.
Crossref
Crossref
John M. Kane, Aleksandar Skuban, John Ouyang, Mary Hobart, Stephanie Pfister, Robert D. McQuade, Margaretta Nyilas, William H. Carson, Raymond Sanchez & Hans Eriksson. (2015) A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophrenia Research 164:1-3, pages 127-135.
Crossref
Crossref
Lin Xiao, Xiaoling Lin, Qingyan Wang, Dali Lu & Siyuan Tang. (2015) Adaptation and validation of the “cognitive complaints in bipolar disorder rating assessment” (COBRA) in Chinese bipolar patients. Journal of Affective Disorders 173, pages 226-231.
Crossref
Crossref
Fenneke M. van Hasselt, Paul F. M. Krabbe, Maarten J. Postma & Anton J. M. Loonen. (2014) Evaluation of health promotion programmes in severe mental illness: theory and practice. International Journal of Methods in Psychiatric Research 24:1, pages 83-97.
Crossref
Crossref
María P. Garcia-Portilla, Jesús J. Gomar, María Teresa Bobes-Bascaran, Isabel Menendez-Miranda, Pilar Alejandra Saiz, José Muñiz, Celso Arango, Thomas Patterson, Philip Harvey, Julio Bobes & Terry Goldberg. (2014) Development of the Spanish Brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder. Revista de Psiquiatría y Salud Mental (English Edition) 7:3, pages 113-120.
Crossref
Crossref
María Paz Garcia-Portilla, Jesús Gomar, María Teresa Bobes-Bascaran, Isabel Menendez-Miranda, Pilar Alejandra Saiz, José Muñiz, Celso Arango, Thomas Patterson, Philip Harvey, Julio Bobes & Terry Goldberg. (2014) Desarrollo de la versión española de la Escala Breve para la Evaluación de la Capacidad Funcional [Sp-UPSA-Brief] para pacientes con esquizofrenia y trastorno bipolar. Revista de Psiquiatría y Salud Mental 7:3, pages 113-120.
Crossref
Crossref
A. Millier, U. Schmidt, M.C. Angermeyer, D. Chauhan, V. Murthy, M. Toumi & N. Cadi-Soussi. (2014) Humanistic burden in schizophrenia: A literature review. Journal of Psychiatric Research 54, pages 85-93.
Crossref
Crossref
Niklas Granö, Marjaana Karjalainen, Virve Edlund, Erkki Saari, Arja Itkonen, Jukka Anto & Mikko Roine. (2013) Health‐related quality of life among adolescents: a comparison between subjects at risk for psychosis and other help seekers. Early Intervention in Psychiatry 8:2, pages 163-169.
Crossref
Crossref
Adriana Bohórquez Peñaranda, Carlos Gómez Restrepo, Gabriel Fernando Oviedo Lugo, Ana María de la Hoz Bradford, Sergio Mario Castro Díaz, Jenny García Valencia, Luis Eduardo Jaramillo González & Mauricio Ávila-Guerra. (2014) Modalidades de atención para el paciente adulto con diagnóstico de esquizofrenia en fase aguda y de mantenimiento. Revista Colombiana de Psiquiatría 44, pages 101-109.
Crossref
Crossref
Anneli Pitkänen & Kristiina Puolakka. (2013) Effectiveness of psychological and psychosocial interventions on quality of life of patients with schizophrenia and related disorders: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports 11:6, pages 157-168.
Crossref
Crossref
Miguel Gutiérrez Fraile, Jesús J. de la Gándara Martín & Julio Bobes García. (2013) Switching to Ziprasidone in the Clinical Practice Setting: An Open-Label Study. The International Journal of Psychiatry in Medicine 45:2, pages 125-142.
Crossref
Crossref
Maritta Välimäki, Heli Hätönen, Mari Lahti, Lauri Kuosmanen & Clive E Adams. (2012) Information and communication technology in patient education and support for people with schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
. 2012. Qu'est-ce que les psychoses ?. Qu'est-ce que les psychoses ?
99
125
.
Singaravelu Thiyagarajan & Parthipan Sivaraman. (2012) Aripiprazole dose for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
W. Wolfgang Fleischhacker & Alex Hofer. 2012. Handbuch der Psychopharmakotherapie. Handbuch der Psychopharmakotherapie
937
960
.
Angel L Montejo, Javier Correas Lauffer, Jesús Cuervo, Pablo Rebollo, Luis Cordero, Teresa Diez & Jorge Maurino. (2011) Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the 'Tolerability and quality of life' (TOOL) questionnaire. Annals of General Psychiatry 10:1.
Crossref
Crossref
María Paz Garcia-Portilla, Pilar Alejandra Saiz, Manuel Bousoño, María Teresa Bascaran, Carlos Guzmán-Quilo & Julio Bobes. (2011) Validación de la versión española de la escala de Funcionamiento Personal y Social en pacientes ambulatorios con esquizofrenia estable o inestable. Revista de Psiquiatría y Salud Mental 4:1, pages 9-18.
Crossref
Crossref
María Paz Garcia-Portilla, Pilar Alejandra Saiz, Manuel Bousoño, María Teresa Bascaran, Carlos Guzmán-Quilo & Julio Bobes. (2011) Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. Revista de Psiquiatría y Salud Mental (English Edition) 4:1, pages 9-18.
Crossref
Crossref
Michael S. Ritsner. 2011. Handbook of Schizophrenia Spectrum Disorders, Volume II. Handbook of Schizophrenia Spectrum Disorders, Volume II
165
194
.
Celso Arango & William T. Carpenter. 2010. Schizophrenia. Schizophrenia
09
23
.
Claire E. McKibben, Trisha A. Jenkins, Hayley N. Adams, Michael K. Harte & Gavin P. Reynolds. (2010) Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. Behavioural Brain Research 208:1, pages 132-136.
Crossref
Crossref
Melina Siamouli, Katerina Moutou, Eleonora Pantoula, Stamatia Magiria, Irini Chatzivasileiou, Konstantinos Arapidis, Achileas Chatzivasileiou, Simeon Deres & Konstantinos N Fountoulakis. (2009) Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-20). Annals of General Psychiatry 8:1.
Crossref
Crossref
Trisha A. Jenkins, Michael K. Harte, Claire E. McKibben, Jennifer J. Elliott & Gavin P. Reynolds. (2008) Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. Behavioural Brain Research 194:2, pages 230-235.
Crossref
Crossref
Eva Goppoldova, Eva Dragomirecka, Lucie Motlova & Tomas Hajek. (2008) Subjective Quality of Life in Psychiatric Patients: Diagnosis and Illness-Specific Profiles. The Canadian Journal of Psychiatry 53:9, pages 587-593.
Crossref
Crossref